$170.400
+4.209 (+2.47%)Zum Schluss
BCPC-News
BCPC-Events
Balchem Q3 Revenue of $290.66M Beats Expectations
Reports Q3 revenue $290.66M, consensus $289.25M. Ted Harris, chairman, president and CEO of Balchem, said, "Balchem delivered another excellent quarter, with healthy growth across all three of our reporting segments and record consolidated quarterly net sales, net earnings, and adjusted EBITDA."
Balchem Reports Q2 Revenue of $284M
Reports Q2 revenue $284M, consensus $268.5M. Ted Harris, Chairman, President and CEO of Balchem, said, "The second quarter was another very strong quarter for Balchem with healthy growth in all three of our reporting segments. On a consolidated basis, we delivered record quarterly net sales, net earnings, and adjusted EBITDA, as well as solid cash flows."
Balchem Q1 Revenue $270.71M Beats Consensus
Reports Q1 revenue $270.71M, consensus $266.5M. Ted Harris, Chairman, President and CEO of Balchem said, "The first quarter was an excellent start to the year for Balchem, with sales and earnings growth in all three segments. We delivered record first quarter net sales, adjusted EBITDA, and net earnings, as well as strong cash flows."
Balchem Launches Metalosate T.E.A.M. Plant Tissue Analysis Platform
Balchem Plant Nutrition announced the launch of its Metalosate T.E.A.M. plant tissue analysis digital platform. "The platform helps advisors optimize nutrient balance to enhance yield potential and crop quality, while reducing unnecessary input cost in specialty crops. Built as a free service for pest control advisors and agronomists, T.E.A.M. translates plant tissue analysis results into targeted nutrition recommendations that growers can act on with confidence," the company said.
Balchem Reports Q4 Revenue of $263.6M
Reports Q4 revenue $263.6M, consensus $259.59M. Ted Harris, Chairman, President, and CEO of Balchem said, "In the fourth quarter, Balchem's strong growth trajectory continued. We delivered record fourth quarter net sales and adjusted EBITDA, with top and bottom line growth year over year in each of our three segments, driven by ongoing progress on our focused growth platforms and our company's alignment with the favorable 'better for you' trends."
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.